In a groundbreaking multi-site investigation conducted across Denmark, researchers have uncovered strikingly high prevalence rates of post-traumatic stress disorder (PTSD) among individuals undergoing treatment for substance use disorders (SUD). Published recently in BMC Psychiatry, the study rigorously applies the latest ICD-11 criteria for PTSD, offering a comprehensive evaluation of trauma-related psychiatric symptoms in this vulnerable population. This extensive research not only enhances our understanding of comorbidities in SUD treatment but also signals urgent clinical implications for tailored interventions.
The study draws its strength from a robust sample size of 1,347 adults actively seeking treatment across five Danish facilities specializing in SUD care. By utilizing structured clinical interviews explicitly aligned with ICD-11 diagnostics, the research team was able to delineate subgroups with probable PTSD and subclinical symptomatology. Their findings reveal that approximately one in four patients meet the threshold for probable PTSD—a prevalence rate that is alarmingly high compared to the general population. This underscores the profound intersection between trauma and substance dependence that clinicians must navigate.
Differentiating between types of substance use disorders, the analysis makes a critical distinction between those treated primarily for alcohol use disorder (AUD) and those receiving treatment for drug use disorder (DUD). Notably, PTSD prevalence was found to be significantly elevated in the DUD cohort. This elevation points toward distinctive trauma profiles and perhaps varied etiological pathways contributing to substance misuse. The study suggests that individuals with drug dependencies may experience not only higher trauma exposure but also more complex symptom clusters that complicate treatment trajectories.
Beyond PTSD prevalence, the study offers a nuanced comparison of the sociodemographic and clinical landscapes distinguishing AUD and DUD populations. Social functioning—a critical determinant of recovery prospects—differed substantially between groups, indicating the layered challenges faced by patients. Those in DUD treatment displayed more pronounced impairments across various social parameters, exacerbating the clinical complexity and signaling the necessity for integrated therapeutic frameworks that address both trauma and social rehabilitation.
Addressing the specific criteria of ICD-11 PTSD employed in the research is essential to appreciating the study’s rigor. ICD-11 conceptualizes PTSD with an emphasis on disturbances in re-experiencing, avoidance, and heightened threat perception, streamlining earlier definitions and enhancing diagnostic consistency globally. By applying these standards, the Danish study elevates its relevance to international clinical practice, offering a replicable model for assessing trauma in substance-dependent populations.
From a neuropsychological perspective, the interplay between trauma-induced neurobiological alterations and substance use behaviors introduces formidable hurdles. Traumatic stress is known to dysregulate the hypothalamic-pituitary-adrenal (HPA) axis and alter neurotransmitter systems such as dopamine and glutamate pathways, which are intricately involved in reward and addiction mechanisms. These neurochemical disruptions may partly explain the heightened PTSD rates observed and justify integrated treatment modalities that target both addiction circuitry and trauma processing.
The public health implications of these findings are profound. Substance use disorders already constitute a major global health burden, but the revelation that up to 40% of individuals battling SUD exhibit PTSD symptoms or subclinical manifestations necessitates policy-level interventions. Treatment programs must expand beyond conventional paradigms, incorporating trauma-informed care principles to mitigate the risk of relapse and optimize recovery outcomes.
The study also flags clinical distinctions vital for personalized medicine approaches. Given that those treated for drug use disorders experience elevated PTSD prevalence and greater social dysfunction, clinicians are urged to develop dual-focused interventions. Therapeutic modalities such as Seeking Safety or Trauma-Informed Cognitive Behavioral Therapy (CBT) may hold promise, but require adaptation to the specific cultural and healthcare context of Danish or similar European populations.
In addition to clinical recommendations, the research opens avenues for future investigations, including longitudinal designs to track PTSD symptom trajectories post-treatment and the efficacy of targeted trauma interventions within SUD programs. It also invites exploration of genetic and epigenetic moderators influencing susceptibility to trauma and addiction comorbidity.
Importantly, the authors emphasize the need for systematic PTSD screening in all SUD treatment settings, highlighting that overlooked trauma symptoms may undermine treatment engagement and success. The findings strongly advocate for increased training among addiction specialists to recognize and manage PTSD within their patient populations effectively.
Moreover, the research community stands to gain from replicating such methodologically rigorous studies in diverse demographic and healthcare environments. This would facilitate the validation of these findings beyond Denmark and potentially contribute to the development of internationally standardized care pathways addressing PTSD within SUD treatment frameworks.
Intriguingly, the study underscores the bidirectional nature of PTSD and substance use disorders, suggesting that trauma symptom severity may drive substance misuse as a form of self-medication, which in turn exacerbates PTSD symptoms—a vicious cycle that demands comprehensive breaking points. Such insights enrich the biopsychosocial model of addiction and emphasize trauma’s central role.
In conclusion, this pioneering Danish multi-site study published in BMC Psychiatry delineates a compelling portrait of comorbidity between trauma and substance use disorders, advocating for trauma-informed clinical care and policy reforms. It accentuates the urgent requirement for customized interventions, especially targeting individuals in DUD treatment, where PTSD prevalence and psychosocial dysfunction peak. These findings chart a transformative course for addiction psychiatry, recognizing trauma’s pervasive influence and the promise of integrative, informed therapeutic responses.
Subject of Research: The prevalence and impact of ICD-11 PTSD diagnoses among individuals receiving substance use disorder treatment in Denmark, with a comparative focus on alcohol versus drug use disorder populations.
Article Title: Trauma and ICD-11 PTSD in substance use disorder treatment: a Danish multi-site study
Article References:
Karsberg, S., Najavits, L., Pedersen, M. et al. Trauma and ICD-11 PTSD in substance use disorder treatment: a Danish multi-site study. BMC Psychiatry 25, 770 (2025). https://doi.org/10.1186/s12888-025-07164-w
Image Credits: AI Generated
